Modulating The
Immune System
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Fighting Inflammatory Diseases
Obefazimod—Abivax's lead drug candidate—is an oral, first-and-only small molecule with a novel mechanism of action that demonstrates enhanced expression of miR-124, which plays a critical role in the regulation of the inflammatory response.
Currently, obefazimod is being tested in phase 3 trials for the treatment of adults with moderately to severely active ulcerative colitis (UC). The initiation of these late-stage trials is building upon the success of the obefazimod phase 2 trials, which demonstrated an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores.
Abivax is also initiating a phase 2a clinical trial for obefazimod in Crohn's disease (CD) in Q1 2024.
Pipeline
Abivax is continuing to develop obefazimod and evaluate other potential inflammatory indications to pursue, while simultaneously exploring follow-on compounds.
| Drug Candidate | Regimen | Indication | Research | Nonclinical | Phase 1 | Phase 2 | Phase 3 | Anticipated milestones |
|---|---|---|---|---|---|---|---|---|
| Obefazimod | ||||||||
|
Monotherapy | Moderately to Severely Active Ulcerative Colitis (UC) |
||||||||
| Obefazimod | Monotherapy | Moderately to Severely Active Ulcerative Colitis (UC) |
Status:
|
Anticipated Milestones:
|
||||
| Monotherapy | Crohn's Disease (CD) | ||||||||
| Monotherapy | Crohn's Disease (CD) |
Status:
|
Anticipated Milestones:
|
|||||
| Combination therapy | Moderately to Severely Active Ulcerative Colitis (UC) | ||||||||
| Combination therapy | Moderately to Severely Active Ulcerative Colitis (UC) |
Status:
|
Anticipated Milestones:
|
|||||
| Monotherapy | Other Inflammatory Indications | ||||||||
| Monotherapy | Other Inflammatory Indications |
Status:
|
Anticipated Milestones:
|
|||||
| 1. Decision subject to results of phase 3 monotherapy induction trials | ||||||||
Ulcerative Colitis
Obefazimod is an oral, small-molecule drug candidate in clinical development for the treatment of moderately to severely active UC and has demonstrated anti-inflammatory activity in preclinical studies and in both phase 2a and phase 2b clinical trials.
Crohn's Disease
Abivax believes obefazimod may result in beneficial effects for patients suffering from CD due to the similar pathophysiology to UC. As a result, Abivax plans on initiating a phase 2a clinical trial to potentially demonstrate outcomes consistent with those observed in the phase 2 clinical trials for UC.